157 related articles for article (PubMed ID: 36319553)
1. 5α-reductase inhibitors and the risk of bladder cancer in a large, population-based cohort.
Dekalo S; McArthur E; Campbell J; Ordon M; Power N; Welk B
Urol Oncol; 2023 Jan; 41(1):50.e11-50.e17. PubMed ID: 36319553
[TBL] [Abstract][Full Text] [Related]
2. Comparing Clinical and Economic Outcomes Associated with Early Initiation of Combination Therapy of an Alpha Blocker and Dutasteride or Finasteride in Men with Benign Prostatic Hyperplasia in the United States.
DerSarkissian M; Xiao Y; Duh MS; Lefebvre P; Swensen AR; Bell CF
J Manag Care Spec Pharm; 2016 Oct; 22(10):1204-14. PubMed ID: 27668569
[TBL] [Abstract][Full Text] [Related]
3. Risk of rhabdomyolysis from 5-α reductase inhibitors.
Welk B; McArthur E; Ordon M; Dirk J; Dixon S; Garg AX
Pharmacoepidemiol Drug Saf; 2018 Mar; 27(3):351-355. PubMed ID: 29368380
[TBL] [Abstract][Full Text] [Related]
4. Association of Suicidality and Depression With 5α-Reductase Inhibitors.
Welk B; McArthur E; Ordon M; Anderson KK; Hayward J; Dixon S
JAMA Intern Med; 2017 May; 177(5):683-691. PubMed ID: 28319231
[TBL] [Abstract][Full Text] [Related]
5. Bladder Cancer Survival of Men Receiving 5α-Reductase Inhibitors.
Mäkelä VJ; Kotsar A; Tammela TLJ; Murtola TJ
J Urol; 2018 Oct; 200(4):743-748. PubMed ID: 29730200
[TBL] [Abstract][Full Text] [Related]
6. Impact of 5α-reductase inhibitor and α-blocker therapy for benign prostatic hyperplasia on prostate cancer incidence and mortality.
Van Rompay MI; Curtis Nickel J; Ranganathan G; Kantoff PW; Solomon KR; Lund JL; McKinlay JB
BJU Int; 2019 Mar; 123(3):511-518. PubMed ID: 30216624
[TBL] [Abstract][Full Text] [Related]
7. Incidence of type 2 diabetes mellitus in men receiving steroid 5α-reductase inhibitors: population based cohort study.
Wei L; Lai EC; Kao-Yang YH; Walker BR; MacDonald TM; Andrew R
BMJ; 2019 Apr; 365():l1204. PubMed ID: 30971393
[TBL] [Abstract][Full Text] [Related]
8. A large retrospective analysis of acute urinary retention and prostate-related surgery in BPH patients treated with 5-alpha reductase inhibitors: dutasteride versus finasteride.
Issa MM; Runken MC; Grogg AL; Shah MB
Am J Manag Care; 2007 Feb; 13 Suppl 1():S10-6. PubMed ID: 17295600
[TBL] [Abstract][Full Text] [Related]
9. Rates of prostate surgery and acute urinary retention for benign prostatic hyperplasia in men treated with dutasteride or finasteride.
Kuiper JG; Bezemer ID; Driessen MT; Vasylyev A; Roehrborn CG; Penning-van Beest FJ; Herings RM
BMC Urol; 2016 Aug; 16(1):53. PubMed ID: 27580700
[TBL] [Abstract][Full Text] [Related]
10. A population-based study of the risk of osteoporosis and fracture with dutasteride and finasteride.
Antoniou T; Macdonald EM; Yao Z; Gomes T; Tadrous M; Ho JM; Mamdani MM; Juurlink DN;
BMC Musculoskelet Disord; 2018 May; 19(1):160. PubMed ID: 29789004
[TBL] [Abstract][Full Text] [Related]
11. MRI characterization of the dynamic effects of 5α-reductase inhibitors on prostate zonal volumes.
Truong H; Logan J; Turkbey B; Siddiqui MM; Rais-Bahrami S; Hoang AN; Pusateri C; Shuch B; Walton-Diaz A; Vourganti S; Nix J; Stamatakis L; Harris C; Chua C; Choyke PL; Wood BJ; Pinto PA
Can J Urol; 2013 Dec; 20(6):7002-7. PubMed ID: 24331340
[TBL] [Abstract][Full Text] [Related]
12. Association of 5α-Reductase Inhibitors With Dementia, Depression, and Suicide.
Garcia-Argibay M; Hiyoshi A; Fall K; Montgomery S
JAMA Netw Open; 2022 Dec; 5(12):e2248135. PubMed ID: 36547981
[TBL] [Abstract][Full Text] [Related]
13. The risk of dementia with the use of 5 alpha reductase inhibitors.
Welk B; McArthur E; Ordon M; Morrow SA; Hayward J; Dixon S
J Neurol Sci; 2017 Aug; 379():109-111. PubMed ID: 28716218
[TBL] [Abstract][Full Text] [Related]
14. 5α-Reductase inhibitors and risk of high-grade or lethal prostate cancer.
Preston MA; Wilson KM; Markt SC; Ge R; Morash C; Stampfer MJ; Loda M; Giovannucci E; Mucci LA; Olumi AF
JAMA Intern Med; 2014 Aug; 174(8):1301-7. PubMed ID: 24887392
[TBL] [Abstract][Full Text] [Related]
15. Association of 5α-Reductase Inhibitor Prescription With Bladder Cancer Progression in Males in South Korea.
An MH; Kim MS; Kim C; Noh TI; Joo KJ; Lee DH; Yi KH; Kwak JW; Hwang TH; Park RW; Kang SH
JAMA Netw Open; 2023 May; 6(5):e2313667. PubMed ID: 37191958
[TBL] [Abstract][Full Text] [Related]
16. Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis.
Corona G; Tirabassi G; Santi D; Maseroli E; Gacci M; Dicuio M; Sforza A; Mannucci E; Maggi M
Andrology; 2017 Jul; 5(4):671-678. PubMed ID: 28453908
[TBL] [Abstract][Full Text] [Related]
17. Clinical effects and economical impact of dutasteride and finasteride therapy in Italian men with LUTS.
Cindolo L; Berardinelli F; Fanizza C; Romero M; Pirozzi L; Tamburro FR; Pellegrini F; Neri F; Pitrelli A; Schips L
Arch Ital Urol Androl; 2013 Dec; 85(4):200-6. PubMed ID: 24399122
[TBL] [Abstract][Full Text] [Related]
18. The effects of dutasteride and finasteride on BPH-related hospitalization, surgery and prostate cancer diagnosis: a record-linkage analysis.
Cindolo L; Fanizza C; Romero M; Pirozzi L; Autorino R; Berardinelli F; Schips L
World J Urol; 2013 Jun; 31(3):665-71. PubMed ID: 23239103
[TBL] [Abstract][Full Text] [Related]
19. Five-alpha-reductase Inhibitors for prostate cancer prevention.
Wilt TJ; MacDonald R; Hagerty K; Schellhammer P; Kramer BS
Cochrane Database Syst Rev; 2008 Apr; (2):CD007091. PubMed ID: 18425978
[TBL] [Abstract][Full Text] [Related]
20. High Real-World Medication Adherence and Durable Clinical Benefit in Medicare Patients Treated with 5-Alpha Reductase Inhibitors for Benign Prostatic Hyperplasia.
Zhang H; Frendl DM; Wang Z; Olumi AF
J Urol; 2020 Aug; 204(2):325-331. PubMed ID: 32167867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
